Wir sind mit live! Mehr erfahren

Anika Therapeutics

ANIK

Börsenwert 267 Mio. $

19,98 USD

-0,71

3,43 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

1 Tag

-3,43 %

5 Tage

2,3 %

1 Monat

-4,13 %

3 Monate

26,3 %

6 Monate

29,82 %

Seit Jahresbeginn

113,69 %

1 Jahr

119,8 %

5 Jahre

-51,28 %

10 Jahre

-55,33 %

Profil: Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Mitarbeiter: 235

Gesundheitswesen Arzneimittelhersteller – Spezialpräparate und Generika

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 90 %

Neutral 10 %

Negativ 0 %

Zacks Investment Research

Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?

Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.

Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?

Zacks Investment Research

Best Momentum Stocks to Buy for August 26th

BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.

Best Momentum Stocks to Buy for August 26th

Zacks Investment Research

Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why

Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks Investment Research

Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?

ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.

Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?

Zacks Investment Research

5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns

Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.

5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns

Zacks Investment Research

Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know

Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know

Zacks Investment Research

5 Stocks With Recent Price Strength to Tap August Rally

Five stocks, including OPHC, EDRY, ENVA, ANIK and GEO, show strong recent price gains and earnings growth as markets rally.

5 Stocks With Recent Price Strength to Tap August Rally

Zacks Investment Research

Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable

Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable

Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript

Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript

Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript

Anika Therapeutics Q2 Earnings Call Highlights

Anika Therapeutics NASDAQ: ANIK reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and manufacturing improvements supported profitability.

Anika Therapeutics Q2 Earnings Call Highlights

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt